Imagine four adults who smoke cigarettes and want another source of nicotine.
In the United States, an adult can buy selected nicotine pouches whose manufacturer is authorised to say that switching completely from cigarettes reduces specific health risks. In the United Kingdom, an adult can buy a regulated vape or nicotine pouch as an ordinary consumer, although age controls, marketing restrictions, and vaping excise are tightening. In Australia, the same adult can buy cigarettes from a supermarket, petrol station or tobacconist, but must visit a participating pharmacy for a legal vape and cannot lawfully obtain a nicotine pouch at all. In New Zealand, regulated vapes remain consumer products sold by general and specialist retailers, although disposables are banned and products are hidden from view, while ordinary access to nicotine pouches is effectively closed.
The nicotine is not fundamentally different in Washington, London, Melbourne, and Wellington. Combustion remains the overwhelmingly dangerous part of smoking, young people require protection, and none of these governments regards nicotine products as harmless. Yet each has created a profoundly different market.
The usual explanation is evidence. One country is said to be following the science, while another has misunderstood it, surrendered to industry, or embraced ideology. That explanation is inadequate because these countries are not merely interpreting evidence differently. They are answering different moral questions about commerce, autonomy, and acceptable risk.
The United States asks whether a manufacturer can prove that a particular product and claim will benefit population health. The United Kingdom asks how the government can preserve a route away from smoking while making the nicotine market less attractive to children. Australia asks whether recreational nicotine commerce should exist outside the cigarette market. New Zealand asks whether adult access can be maintained while the visibility and youth appeal of vaping are contained.
These are scientific questions, but they are also competing philosophies of government.
The American model is often described as permissive because nicotine pouches and vaping products are widely available, but legally, it is anything but casual. The Food and Drug Administration requires new products to pass through a premarket process in which the manufacturer must show that allowing a specific product onto the market would be appropriate for the protection of public health. The assessment considers the entire population, including existing tobacco users who might switch, people who might begin using the product, and young people who might be attracted to it.
Permission to sell a product is separate from permission to describe it as less harmful. To make a modified-risk claim, a manufacturer must persuade the FDA that the proposed wording is scientifically accurate, understood by consumers, and likely to benefit the population as a whole.
In January 2025, the FDA authorised 20 ZYN nicotine pouch products after concluding that their lower levels of harmful constituents and potential to move adults away from cigarettes outweighed the risks. In June 2026, it allowed those products to carry a specific claim:
“Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”
That is an extraordinary sentence in international nicotine policy. It does not say the products are harmless, recommend nicotine to non-users, or grant every pouch the same status. The authorisation applies to named products in specified strengths, is supported by a particular evidence package, and can be withdrawn if later evidence changes the population-health calculation.
The American government is therefore not saying that nicotine pouches are safe. It is saying that, for these products used instead of cigarettes, a comparative-risk statement is sufficiently accurate and beneficial that adults may be told it.
This is regulated autonomy. It assumes that adults make better choices when governments distinguish among products rather than compressing everything containing nicotine into one warning. It also accepts that a company may communicate a health-relevant fact if the claim survives regulatory scrutiny.
The model has weaknesses. Applications are slow, expensive, and technically demanding, which favours large companies. Product-by-product assessment can also produce a strange market in which a small number of products are formally authorised while many unauthorised products remain readily available. The system is intellectually precise but administratively cumbersome.
Its moral answer is nevertheless clear: commerce is permissible after evidence is supplied, and truthful risk claims may be allowed when they can help adults move away from smoking. A manufacturer does not have an automatic right to make such claims, but neither does the government have an automatic right to keep consumers uninformed.
The British model begins from a different premise. UK public-health authorities have long said that vaping is not risk-free but is substantially less harmful than smoking and can help adults quit. Vaping has therefore remained an ordinary consumer activity rather than being confined to prescription or pharmacy supply.
This is not laissez-faire. Single-use vapes were banned in June 2025, and the Tobacco and Vapes Act became law in April 2026, creating stronger controls over sales, advertising, sponsorship, displays, packaging and products designed to appeal to children. From 29 October 2026, selling any vaping or nicotine product to someone under 18 will be an offence. From January 2027, people born on or after 1 January 2009 will never legally be sold cigarettes as they age.
The UK will also introduce a vaping-products duty of £2.20 per 10 millilitres of liquid from 1 October 2026, accompanied by a further increase in tobacco duty.
The British bargain is controlled commerce. Adults remain consumers capable of choosing a less harmful alternative, while children are treated as people whose future autonomy could be damaged by addiction. The market may serve adults, but it may not freely recruit the next generation.
Excise makes this balance more difficult. A moderate tax can raise revenue and help normalise vaping as a regulated market, but an excessive tax could narrow the price advantage that encourages smokers to switch. Introducing the duty alongside higher tobacco taxes suggests the government understands that distinction. Whether the gap remains large enough will matter more than the mere existence of the tax.
Britain’s answer is that access and control can coexist. An adult may buy the product, a company may sell it, and the government may tax it, restrict its presentation, regulate its contents, and prohibit youth sales while still telling smokers that switching is preferable to continuing to inhale smoke.
Australia has chosen the most restrictive model. Vapes, whether or not they contain nicotine, may legally be sold only through pharmacies for smoking cessation or the management of nicotine dependence. Adults can obtain eligible lower-strength products without a prescription where local laws permit, but they must speak with a pharmacist. Products are restricted to mint, menthol and tobacco flavours; packaging is pharmaceutical; disposables are excluded, and higher nicotine concentrations require a prescription.
Even these products occupy an unusual position. Vapes on the TGA’s notified list are not registered medicines fully evaluated for quality, safety and efficacy. They are unapproved therapeutic goods whose sponsors have notified the regulator that they comply with applicable standards.
Australia therefore permits vaping while refusing to recognise an ordinary consumer vaping market. The adult must appear as a patient seeking treatment, not a consumer choosing among nicotine products.
For nicotine pouches, the position is more severe. Since 24 July 2026, consumers have been unable to lawfully buy or personally import them. Doctors cannot prescribe them, pharmacies cannot supply them, and previous unapproved-goods pathways have been closed. A manufacturer could seek inclusion in the Australian Register of Therapeutic Goods, but no nicotine pouch is currently included. In practical terms, ordinary access has been eliminated.
The contrast with America is stark. One regulator has authorised selected pouches and allowed a specific claim that switching from cigarettes lowers several disease risks. Another has closed the existing consumer, importation, prescribing, and pharmacy pathways because no pouch has been registered as a medicine.
The evidence did not transform when it crossed the Pacific. The institutions asked different questions. The FDA asked whether specified products could produce a net population-health benefit. Australia asked whether an unregistered nicotine product should remain available through therapeutic channels. Once the question is framed that way, prohibition becomes the default.
This is therapeutic paternalism. It reflects deep suspicion of commercial nicotine outside established pharmaceutical products and assumes that professional mediation is protective, consumer appeal is dangerous, and access should be justified by therapeutic purpose rather than individual preference.
Those concerns are not imaginary. Nicotine companies want customers, appealing products can attract non-smokers, and commercial incentives do not reliably distinguish between recruiting a new user and helping a smoker switch. But the Australian model produces an unavoidable contradiction: combustible cigarettes remain ordinary consumer products available from thousands of retailers without consultation or therapeutic purpose.
A product that delivers nicotine by burning tobacco therefore enjoys a clearer legal pathway than a vape, while a pouch that produces no smoke has no ordinary pathway at all. The system is strictest not with the most dangerous product, but with products that are newer and institutionally unfamiliar.
Australia may believe it has rejected nicotine commerce. In reality, it has preserved cigarette commerce while pushing demand for alternatives towards pharmacies or illegal suppliers. The moral ambition is protection; the practical danger is that protection from a regulated market becomes exposure to an unregulated one.
New Zealand does not fit neatly into either the British or Australian camp. General retailers such as dairies, supermarkets and petrol stations may sell notified vaping products in tobacco, mint and menthol flavours, while approved specialist vape retailers may sell a wider range. The purchaser does not need a prescription or clinical justification.
At the same time, New Zealand has tightened the architecture surrounding access. Sales to people under 18 are prohibited; new specialist stores must meet distance requirements from schools, marae and early childhood centres; disposable devices have been banned since June 2025; products must be hidden in general retailers; specialist stores cannot display them so they are visible from outside, and online promotion is heavily restricted.
The product may be sold, but it should not dominate the visual environment. Adults may seek it out, but children should not encounter it as a colourful invitation.
This is pragmatic containment. It recognises that regulated vapes may help adults move away from cigarettes and that closing the legal market could have serious unintended consequences, while accepting that the industry can expand beyond its original harm-reduction purpose.
New Zealand has also repealed legislation that would have dramatically reduced tobacco retailers, imposed very-low-nicotine cigarette standards, and created a smoke-free generation. It preserved the consumer vaping market but strengthened its boundaries, suggesting a willingness to revise policy rather than pursue a single philosophy of prohibition.
Nicotine pouches expose the limits of that pragmatism. Tobacco-derived oral nicotine products cannot be imported for retail sale unless approved as medicines, while synthetic recreational pouches require approval through the psychoactive-substances framework. Ordinary retail access is therefore unavailable.
New Zealand is liberal about the lower-risk product already integrated into its system, vaping, but highly cautious about a newer category seeking entry. The question is not only whether pouches are less harmful than smoking, but whether the country needs another nicotine category. That is a judgement about the desired shape of the market, not toxicology alone.
The four systems can be understood by asking what each fears most. The United States fears an unproven product or misleading claim, so it demands evidence and grants product-specific permission. The United Kingdom fears losing the harm-reduction value of adult access while allowing an industry to recruit children, so it combines commerce with age controls, marketing restrictions, and taxation. Australia fears the normalisation of nicotine itself, so it medicalises alternatives and closes categories that have not become medicines. New Zealand fears youth recruitment and commercial saturation but also fears losing a legal substitute for smoking, so it preserves access while reducing visibility and promotion.
None of these fears is imaginary. Manufacturers can mislead, children can become dependent, consumer markets can expand, medical gatekeeping can restrict switching, tax can strengthen illicit trade, and prohibition can transfer demand to criminal suppliers. The disagreement concerns which danger should dominate when they cannot all be eliminated.
Every government says it wants to protect children, but the phrase does not resolve the debate. Age verification, advertising restrictions, and penalties for underage sales protect children. Yet a policy that implies vaping or pouches are as dangerous as cigarettes can distort risk perceptions, while eliminating a legal market without eliminating demand may expose young people to sellers with no reason to verify age.
Protecting children should mean preventing initiation, limiting persuasive marketing, enforcing age restrictions, and helping create families and communities with less smoking. These goals often align, but sometimes they conflict. Serious policy begins where the slogan stops.
Adult autonomy also requires more than a free-for-all. Products need manufacturing standards, ingredient disclosure, nicotine limits, child-resistant packaging, accurate labels, and credible enforcement. Regulation can support autonomy, however, or extinguish it.
The American model supports autonomy by permitting precise claims after scrutiny. Britain preserves access while restricting commercial conduct. New Zealand maintains a legal consumer pathway for vaping while containing its visibility. Australia makes choice secondary to clinical supervision and presently offers no choice at all for nicotine pouches.
No system can simply be copied into another country. Institutions, smoking patterns, healthcare systems, political cultures, and illicit markets differ. But every government should answer the same questions: Is combustion the primary target, or nicotine itself? Should adults receive accurate comparative-risk information? Must every lower-risk product become a medicine while cigarettes remain consumer goods? How much inconvenience can be imposed before consumers turn to illegal suppliers?
A coherent policy would begin with a clear hierarchy. People who do not use nicotine should not start. People who smoke should be supported in quitting. Those who cannot or will not quit should be encouraged to move completely away from combustible cigarettes. Products should be regulated according to risk, young people should be protected from sales and promotion, adults should receive truthful information, and legal alternatives should be accessible and affordable enough to compete with cigarettes and illicit supply.
None of the four countries fully achieves that. America has the most sophisticated pathway for evidence and risk communication, but a disorderly wider market. Britain has built the clearest compromise between harm reduction and youth protection, but taxation and further restrictions could erode adult access. Australia has the strongest controls but the weakest risk proportionality. New Zealand preserves a practical consumer route for vaping while remaining reluctant to admit new nicotine categories.
These are four different answers to the same moral problem: how much risk an adult may choose, how much persuasion a company may use, and how much uncertainty society should tolerate to reduce a larger established harm.
Evidence can tell us that smoking is extraordinarily dangerous, that non-combustible products are not risk-free, and that the risks are not equal. It cannot decide whether an adult should be treated as a consumer or a patient, whether truthful commercial speech is a public-health tool, or whether the possibility of youth uptake justifies denying adults a legal alternative.
Those are political choices, and governments should make them honestly.
The United States says, “Prove it.”
The United Kingdom says: sell it, but control it.
New Zealand says: keep it available, but out of sight.
Australia says: medicalise it or remove it.
The ultimate test will not be which country sounds toughest. It will be one that produces fewer smokers, fewer young people dependent on nicotine, fewer customers for illegal suppliers, and fewer deaths from inhaling smoke.
Everything else is moral theatre.
By comparing approaches taken to regulating vaping in the US, UK, New Zealand and Australia, Alan Gor highlights the arbitrary way governments in these four countries have approached the regulation of vaping even though, as Alan reminds us, exactly the same evidence on benefits and risks exists in each of these countries. In 2024, the UK became the first country in the world to provide free vapes and behavioural assistance to one million smokers unable to quit despite multiple attempts. This ‘Swap to Stop’ scheme cost the British government £45 million. Pregnant women struggling to quit smoking were paid £400 if they managed to quit. In contrast, excessively restrictive policies adopted in Australia resulted in 95.7% of vapes being supplied by the black market. Many of us would think that when up to two thirds of long term smokers will die from a smoking related condition and each of them will lose on average 12 years of expected life, and when the number of scientifically attributed deaths worldwide from safer nicotine products is less than the number of fingers on the hands of a lumberjack although about 200 million worldwide now use safer nicotine products, governments would be falling over themselves to ensure that a wide range of safer nicotine products is readily available to all smokers. Alas, that’s not the case. Alan Gor demonstrates the twisted logic and sophistry that creates huge barriers for smokers wanting to switch to less dangerous nicotine options.